HCM14-3wt31
ICGi029-A-3
General
Cell Line |
|
| hPSCreg name | ICGi029-A-3 |
| Cite as: | ICGi029-A-3 |
| Alternative name(s) |
HCM14-3wt31
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 24th October 2024 |
| User feedback | |
Provider |
|
| Generator | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
| Owner | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
| Distributors | |
| Derivation country | Russia |
External Databases |
|
| BioSamples | SAMEA116305377 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA8307097 |
Ethics
Also have a look at the ethics information for the parental line
ICGi029-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | sgRNA (GenScript), Cas9_NLS (NEB), and single-stranded donor oligonucleotides (Biolegio) were used for correction of the c.1543_1545delAAC (p.N515del) mutation in the MYBPC3 gene of patient-specific iPSCs (the ICGi029-A line) |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
ICGi029-A.
|
|
| Passage number reprogrammed | 1 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | ESC-like morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Gelatin | |||||||||||||||||||||
| Feeder cells |
Mouse embryonic fibroblasts |
|||||||||||||||||||||
| Passage method |
Enzymatically
TrypLE
|
|||||||||||||||||||||
| O2 Concentration | 20 % | |||||||||||||||||||||
| CO2 Concentration | 5 % | |||||||||||||||||||||
| Medium |
Other medium:
Base medium: Knock-out DMEM
Main protein source: Knock-out serum replacement Serum concentration: 15 % Supplements
|
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
|||||
| NANOG |
Yes |
|||||
| SSEA-4 |
Yes |
Morphology pictures
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.